Effect of Carvedilol Versus Metoprolol on Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Intervention Therapy

Basit Öğe Kaydı
dc.contributor.authorUguz, Erkan
dc.contributor.authorKurtul, Alparslan
dc.contributor.authorSen, Fatih
dc.date.accessioned2024-09-18T20:08:04Z
dc.date.available2024-09-18T20:08:04Z
dc.date.issued2024
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractCarvedilol can inhibit inflammation, vasoconstriction, and oxidative stress, which play important roles in the development and progression of contrast-induced nephropathy (CIN). To the best of our knowledge, no studies have investigated the potential effect of carvedilol on the prevalence of CIN after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). The present study aimed to determine whether carvedilol use is associated with the development of CIN. A total of 319 patients (mean age, 59.2 +/- 12.4 years; 77.7% male) with ACS who underwent urgent PCI at our institution between May 2019 and May 2022 were included prospectively. Overall, 100 and 219 patients were assigned to the carvedilol and metoprolol groups, respectively. The prevalence of CIN was significantly lower in the carvedilol group (6.0%) than in the metoprolol group (18.3%; P = .003). Multivariate analysis revealed that carvedilol use (odds ratio [OR] .250, 95% confidence interval [CI] .092-.677, P = .006), amount of contrast agent (OR 1.004, 95% CI 1.000-1.008, P = .031), and admission estimated glomerular filtration rate (OR .978, 95% CI 0.960-.995, P = .014) were independently associated with the development of CIN. The use of carvedilol may be a promising option for the prevention of CIN in patients with ACS undergoing urgent PCI.en_US
dc.identifier.doi10.1177/00033197231152572
dc.identifier.endpage330en_US
dc.identifier.issn0003-3197
dc.identifier.issn1940-1574
dc.identifier.issue4en_US
dc.identifier.pmid36647202en_US
dc.identifier.scopus2-s2.0-85147115446en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage323en_US
dc.identifier.urihttps://doi.org/10.1177/00033197231152572
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8598
dc.identifier.volume75en_US
dc.identifier.wosWOS:000915341500001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Incen_US
dc.relation.ispartofAngiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcarvedilolen_US
dc.subjectmetoprololen_US
dc.subjectacute coronary syndromeen_US
dc.subjectcontrast-induced nephropathyen_US
dc.titleEffect of Carvedilol Versus Metoprolol on Contrast-Induced Nephropathy in Patients with Acute Coronary Syndrome Undergoing Percutaneous Intervention Therapyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu